

PATIENT:	GENDER: M	AGE: 51	DOB: 1970
CLIENT NAME:	CLIENT NUMBER: 2141		
PHYSICIAN:	SAMPLE ID:		
COLLECTION DATE: 03/31/2022	DATE RECEIVED: 04/02/2022	REPORT DATE: 04/07/2022	
INDICATION: Lung Cancer	SAMPLE TYPE: Blood		

SOMATIC TESTING RESULTS

Test:	Alteration/Variant:	Result:	Mutant Fraction %
CDK4	amplification	DETECTED	5.75 copies
CHEK2	c.1245_1246delCAinsTG p.K416E	DETECTED	1.56%
GNAS	c.1398_1399delTGinsCT p.A467S	DETECTED	6.11%
POLE	c.3264delTinsCC p.V1089fs*35	DETECTED	7.91%
SMARCA4	c.59delC p.P20fs*23	DETECTED	28.0%
STK11	c.291-2A>T	DETECTED	30.0%
TP53	c.880G>T p.E294*	DETECTED	40.0%
PD-L1*		Positive (≥50%)	
ALK Fusion*		Not Detected	
ROS1 Fusion*		Not Detected	
NTRK1/NTRK2/NTRK3 Fusion*		Pending	
MSI**		Not Detected	

Tested by NGS

* Tested by RT-PCR

**Tested by fragment analysis

DRUG	Drug/biomarker shown effective in patient's tumor type?	Gene/ALTERATION	MUTANT FRACTION	CLINICAL TRIALS‡
palbociclib	N	CDK4	5.75 copies	7
olaparib	N	CHEK2	1.56%	8
pembrolizumab	Y	POLE	7.91%	6
		STK11	30.0%	4
		TP53	40.0%	2
PD-1/PD-L1 targeted agents		PD-L1		

 ‡ For current clinical trial information please visit www.clinicaltrials.gov